Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models.

We have found that EGF-R expression is associated with the development of the Schwann cell-derived tumors characteristic of neurofibromatosis type 1 (NF1) and in animal models of this disease. This is surprising, because Schwann cells normally lack EGF-R and respond to ligands other than EGF. Nevertheless, immunoblotting, Northern analysis, and immunohistochemistry revealed that each of 3 malignant peripheral nerve sheath tumor (MPNST) cell lines from NF1 patients expressed the EGF-R, as did 7 of 7 other primary MPNSTs, a non-NF1 MPNST cell line, and the S100(+) cells from each of 9 benign neurofibromas. Furthermore, transformed derivatives of Schwann cells from NF1(-/-) mouse embryos also expressed the EGF-R. All of the cells or cell lines expressing EGF-R responded to EGF by activation of downstream signaling pathways. Thus, EGF-R expression may play an important role in NF1 tumorigenesis and Schwann cell transformation. Consistent with this hypothesis, growth of NF1 MPNST lines and the transformed NF1(-/-) mouse embryo Schwann cells was greatly stimulated by EGF in vitro and could be blocked by agents that antagonize EGF-R function.

[1]  S. Huson,et al.  Von Recklinghausen neurofibromatosis: a clinical and population study in south-east Wales , 1988 .

[2]  D. Viskochil,et al.  Identification of NF1 mutations in both alleles of a dermal neurofibroma , 1996, Nature Genetics.

[3]  Mark S. Boguski,et al.  Proteins regulating Ras and its relatives , 1993, Nature.

[4]  Karlyne M. Reilly,et al.  Mouse models of tumor development in neurofibromatosis type 1. , 1999, Science.

[5]  F. Collins,et al.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients , 1992, Nature.

[6]  A. Bridges.  The Epidermal Growth Factor Receptor Family of Tyrosine Kinases and Cancer: Can An Atypical Exemplar Be A Sound Therapeutic Target? , 1996, Current Medicinal Chemistry.

[7]  Yosef Yarden,et al.  Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.

[8]  B. Seizinger,et al.  Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. , 1995, Cancer research.

[9]  D. Gutmann,et al.  O-20-295 RAS-GTP levels are elevated in human NF1 peripheral nerve tumors , 1996, Clinical Neurology and Neurosurgery.

[10]  P. Okunieff,et al.  Radiosensitivity in vitro of human soft tissue sarcoma cell lines and skin fibroblasts derived from the same patients. , 1993, International journal of radiation biology.

[11]  M. Lebwohl,et al.  Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[12]  J. Declue,et al.  Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. , 1995, Oncogene.

[13]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[14]  S. Velasco-Miguel,et al.  Mouse tumor model for neurofibromatosis type 1. , 1999, Science.

[15]  S. Colman,et al.  Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene , 1995, Nature Genetics.

[16]  H. Scher,et al.  Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. , 1996, Cancer research.

[17]  V. M. Riccardi,et al.  Von Recklinghausen neurofibromatosis. , 1981, The New England journal of medicine.

[18]  A. Levitzki,et al.  Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.

[19]  X. Estivill,et al.  Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. , 1997, American journal of human genetics.

[20]  E. Sturgis,et al.  Epidermal Growth Factor Receptor Expression by Acoustic Neuromas , 1996, The Laryngoscope.

[21]  Y H Xu,et al.  Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. , 1984, Science.

[22]  R. Wollmann,et al.  S-100 protein in soft-tissue tumors derived from Schwann cells and melanocytes. , 1982, The American journal of pathology.

[23]  B. Korf,et al.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. , 1997, JAMA.

[24]  P. O'Connell,et al.  A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations , 1990, Cell.

[25]  Robert A. Weinberg,et al.  Tumour predisposition in mice heterozygous for a targeted mutation in Nf1 , 1994, Nature Genetics.

[26]  P. O'Connell,et al.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus , 1990, Cell.

[27]  M. Sliwkowski,et al.  The influence of heregulins on human Schwann cell proliferation , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  D. Lowy,et al.  Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis , 1992, Cell.

[29]  V. Riccardi,et al.  Angiogenic and invasive properties of neurofibroma Schwann cells , 1990, The Journal of cell biology.

[30]  J. Declue,et al.  cAMP‐dependent protein kinase A is required for Schwann cell growth: Interactions between the cAMP and neuregulin/tyrosine kinase pathways , 1997, Journal of neuroscience research.

[31]  A. Odén,et al.  Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population , 1997, Cancer.

[32]  M. Lewis,et al.  Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. , 1993, The Journal of biological chemistry.

[33]  B. Brownstein,et al.  Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. , 1990, Science.

[34]  N. Ratner,et al.  Neurofibromatosis Type 1: Genetic and Cellular Mechanisms of Peripheral Nerve Tumor Formation , 1997 .

[35]  I. Pastan,et al.  Retroviruses expressing different levels of the normal epidermal growth factor receptor: Biological properties and new bioassay , 1989, Journal of cellular biochemistry.

[36]  K. North.  Clinical aspects of neurofibromatosis 1. , 1998, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[37]  N. Ratner,et al.  Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase , 1997, Molecular and cellular biology.

[38]  S. Pfeiffer,et al.  Biochemically differentiated neoplastic clone of Schwann cells. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Jeng-Shin Lee,et al.  Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Y H Xu,et al.  Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells , 1985, Molecular and cellular biology.

[41]  F. Otsuka,et al.  A Case of Neurofibrosarcoma Associated with Neurofibromatosis: Light Microscopic, Ultrastructural, Immunohistochemical and Biochemical Investigations , 1990, The Journal of dermatology.

[42]  N. Copeland,et al.  Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. , 1994, Genes & development.